Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer

被引:9
|
作者
Zhang, Hao [1 ]
Ren, Yuan [2 ]
Pang, Deyan [3 ]
Liu, Caigang [1 ]
机构
[1] Dalian Med Univ, Hosp 2, Dept Breast Surg, Dalian 116023, Peoples R China
[2] China Med Univ, Hosp 1, Dept Hematol, Shenyang 110001, Peoples R China
[3] Northeast Yucai Sch, Dept Math, Shenyang 110179, Peoples R China
来源
关键词
Breast cancer; Cancer stem cell; AGBL2; latexin; Survival; STEM-CELLS;
D O I
10.1186/1477-7819-12-142
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We investigated the expression status of AGBL2 and its inhibitor latexin in breast cancer stem cells and its clinical implications in order to lay a foundation for managing breast cancer. Methods: CD44+/CD24- tumor cells (CSC) from clinical specimens were sorted using flow cytometry. AGBL2 expression status was detected in CSC and 126 breast cancer specimens by western blot and immunohistochemistry staining. The relationship between the AGBL2 protein and clinicopathological parameters and prognosis was subsequently determined. Result: As a result, CSC are more likely to generate new tumors in mice and cell microspheres that are deficient in non-obese diabetic/severe combined immunodeficiency mice (NOD/SCID) compared to the control group. The AGBL2 protein was expressed higher in CSC induced to epithelial to mesenchymal transition (EMT) when compared to the control cells, and was found to be related to CSC chemotherapy resistance. After Spearman regression correlation analysis, AGBL2 was observed to be related to clinical stage, histological stage, and lymph node metastasis. In the Cox regression test, the AGBL2 protein was detected as an independent prognostic factor. Through immunoprecipitation, AGBL2 and latexin could form immune complexes. Conclusions: These results demonstrate that AGBL2 is a latexin-interacting protein that regulates the tubulin tyrosination cycle and is a potential target for intervention.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] The expression of β-catenin in different subtypes of breast cancer and its clinical significance
    Li, Shuguang
    Li, Shanshan
    Sun, Ying
    Li, Li
    TUMOR BIOLOGY, 2014, 35 (08) : 7693 - 7698
  • [42] CTLA-4 Expression and Its Clinical Significance in Breast Cancer
    Kern, Rodrigo
    Panis, Carolina
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2021, 69 (01)
  • [43] CTLA-4 Expression and Its Clinical Significance in Breast Cancer
    Rodrigo Kern
    Carolina Panis
    Archivum Immunologiae et Therapiae Experimentalis, 2021, 69
  • [44] Aberrant expression of Arpin in human breast cancer and its clinical significance
    Liu, Xiangping
    Zhao, Bin
    Wang, Haibo
    Wang, Yu
    Niu, Mengdi
    Sun, Ming
    Zhao, Yang
    Yao, Ruyong
    Qu, Zhiqiang
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2016, 20 (03) : 450 - 458
  • [45] Expression of Androgen Receptor in Inflammatory Breast Cancer and Its Clinical Relevance
    Gong, Yun
    Wei, Wei
    Wu, Yun
    Ueno, Naoto T.
    Huo, Lei
    CANCER, 2014, 120 (12) : 1775 - 1779
  • [46] Clinical implications of microRNAs in breast cancer
    Moretti, Erica
    Guarducci, Cristina
    Paladini, Laura
    Di Leo, Angelo
    Santarpia, Libero
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S32 - S34
  • [47] Hypofractionation for breast cancer—clinical implications
    Bruce G. Haffty
    Nature Reviews Clinical Oncology, 2010, 7 : 304 - 306
  • [48] Glycosylation and its implications in breast cancer
    Scott, Danielle A.
    Drake, Richard R.
    EXPERT REVIEW OF PROTEOMICS, 2019, 16 (08) : 665 - 680
  • [49] AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma (vol 414, pg 71, 2018)
    Wang, Li-Li
    Jin, Xiao-Han
    Cai, Mu-Yan
    Li, Hai-Gang
    Chen, Jie-Wei
    Wang, Feng-Wei
    Wang, Chen-Yuan
    Hu, Wei-Wei
    Liu, Fang
    Xie, Dan
    CANCER LETTERS, 2022, 539
  • [50] Molecular heterogeneity of triple-negative breast cancer and its clinical implications
    Irshad, Sheeba
    Ellis, Paul
    Tutt, Andrew
    CURRENT OPINION IN ONCOLOGY, 2011, 23 (06) : 566 - 577